Silexion Therapeutics (SLXN) Projected to Post Quarterly Earnings on Tuesday

Silexion Therapeutics (NASDAQ:SLXN) will likely be announcing its results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.29) per share for the quarter.

Silexion Therapeutics Stock Down 2.7%

NASDAQ SLXN traded down $0.02 during trading on Tuesday, hitting $0.62. 52,932 shares of the company traded hands, compared to its average volume of 57,236. Silexion Therapeutics has a 12 month low of $0.47 and a 12 month high of $22.36. The business has a fifty day simple moving average of $1.30 and a 200 day simple moving average of $2.07. The company has a current ratio of 2.41, a quick ratio of 2.41 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $2.05 million, a P/E ratio of -0.06 and a beta of -0.29.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, March 18th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.